Biogen, Eisai fight back against accusations their big BAN2401 study was skewed -- but this fight isn't over yet
After getting slapped hard by critics for the way it handled their recent trial summary for their Alzheimer’s drug BAN2401, Eisai and their partners at Biogen $BIIB turned up at an Alzheimer’s conference in Barcelona to present their defense of the data after crunching the numbers again. But it’s not playing their way, with Biogen’s stock sliding as key analysts refused to forgive or forget.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.